Comparison of four single-drug regimens on ventricular rate and arrhythmia-related symptoms in patients with permanent atrial fibrillation

American Journal of Cardiology

Volumn 111, Issue 2, 2013, Pages 225-230

  Ulimoen, Sara R ^a   Enger, Steve ^a   Carlson, Jonas ^b   Platonov, Pyotr G ^b   Pripp, Are H ^c   Abdelnoor, Michael ^c   Arnesen, Harald ^d,e   Gjesdal, Knut ^d,e   Tveit, Arnljot ^a  

^a VESTRE VIKEN HOSPITAL TRUST   (Norway)

^b LUND UNIVERSITY   (Sweden)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DILTIAZEM; METOPROLOL; VERAPAMIL;

AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART RATE; HOLTER MONITORING; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYMPTOM CHECKLIST 90; TREATMENT DURATION;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HEART VENTRICLES; HUMANS; MALE; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME;

EID: 84872005941     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2012.09.020     Document Type: Article

References (16)

1. A.J. Camm, P. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, S. Ernst, I.C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, C.R. De, S.J. De, A. Goette, B. Gorenek, M. Heldal, S.H. Hohloser, P. Kolh, J.Y. Le Heuzey, P. Ponikowski, and F.H. Rutten Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J 31 2010 2369 2429
2. V. Fuster, L.E. Ryden, D.S. Cannom, H.J. Crijns, A.B. Curtis, K.A. Ellenbogen, J.L. Halperin, G.N. Kay, J.Y. Le Huezey, J.E. Lowe, S.B. Olsson, E.N. Prystowsky, J.L. Tamargo, L.S. Wann, S.C. Smith Jr., S.G. Priori, N.A. Estes III, M.D. Ezekowitz, W.M. Jackman, C.T. January, J.E. Lowe, R.L. Page, D.J. Slotwiner, W.G. Stevenson, C.M. Tracy, A.K. Jacobs, J.L. Anderson, N. Albert, C.E. Buller, M.A. Creager, S.M. Ettinger, R.A. Guyton, J.L. Halperin, J.S. Hochman, F.G. Kushner, E.M. Ohman, W.G. Stevenson, L.G. Tarkington, and C.W. Yancy 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines Circulation 123 2011 e269 e367
3. R. Farshi, D. Kistner, J.S. Sarma, J.A. Longmate, and B.N. Singh Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens J Am Coll Cardiol 33 1999 304 310
4. T. Nikolaidou, and K.S. Channer Chronic atrial fibrillation: a systematic review of medical heart rate control management Postgrad Med J 85 2009 303 312
5. L.J. Tamariz, and E.B. Bass Pharmacological rate control of atrial fibrillation Cardiol Clin 22 2004 35 45
6. L.S. Jenkins Test-specifications for the Bubien and Kay (Revised Jenkins) Symptom Checklist: Frequency and Severity 1993 University of Maryland Baltimore
7. I.C. Van Gelder, H.F. Groenveld, H.J. Crijns, Y.S. Tuininga, J.G. Tijssen, A.M. Alings, H.L. Hillege, J.A. Bergsma-Kadijk, J.H. Cornel, O. Kamp, R. Tukkie, H.A. Bosker, D.J. van Veldhuisen, and M.P. van den Berg Lenient versus strict rate control in patients with atrial fibrillation N Engl J Med 362 2010 1363 1373
8. G.L. Botto, W. Bonini, and T. Broffoni Modulation of ventricular rate in permanent atrial fibrillation: randomized, crossover study of the effects of slow-release formulations of gallopamil, diltiazem, or verapamil Clin Cardiol 21 1998 837 840
9. R.V. Lewis, E. Laing, T.A. Moreland, E. Service, and D.G. McDevitt A comparison of digoxin, diltiazem and their combination in the treatment of atrial fibrillation Eur Heart J 9 1988 279 283
10. A. Roth, E. Harrison, G. Mitani, J. Cohen, S.H. Rahimtoola, and U. Elkayam Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation Circulation 73 1986 316 324
11. R.V. Lewis, N. Irvine, and D.G. McDevitt Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem Eur Heart J 9 1988 777 781
12. M. Rienstra, I.C. Van Gelder, M.P. van den Berg, F. Boomsma, H.L. Hillege, and D.J. van Veldhuisen A comparison of low versus high heart rate in patients with atrial fibrillation and advanced chronic heart failure: effects on clinical profile, neurohormones and survival Int J Cardiol 109 2006 95 100
13. H.F. Groenveld, H.J. Crijns, M. Rienstra, M.P. van den Berg, D.J. van Veldhuisen, and I.C. Van Gelder Does intensity of rate control influence outcome in persistent atrial fibrillation? Data of the RACE study Am Heart J 158 2009 785 791
14. I.C. Van Gelder, D.G. Wyse, M.L. Chandler, H.A. Cooper, B. Olshansky, V.E. Hagens, and H.J. Crijns Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies Europace 8 2006 935 942
15. T. Tsuneda, T. Yamashita, M. Fukunami, K. Kumagai, S. Niwano, K. Okumura, and H. Inoue Rate control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial Fibrillation (QOLAF) Study Circ J 70 2006 965 970
16. M.R. Reynolds, T. Lavelle, V. Essebag, D.J. Cohen, and P. Zimetbaum Influence of age, sex, and atrial fibrillation recurrence on quality of life outcomes in a population of patients with new-onset atrial fibrillation: the Fibrillation Registry Assessing Costs, Therapies, Adverse events and Lifestyle (FRACTAL) study Am Heart J 152 2006 1097 1103